🔎 Trials Near Me

Utama › Berat Badan Berlebihan › Texas

Kajian klinikal Berat Badan Berlebihan di Texas

55 kajian untuk Berat Badan Berlebihan sedang mencari peserta di lokasi di Texas.

Bandar di Texas

Teks kajian rasmi (Bahasa Inggeris)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Amarillo Medical Specialists /ID# 282380, Amarillo
  • Elligo Clinical Research Center /ID# 282166, Austin
  • JCCT - Juno Bellaire /ID# 282263, Bellaire
  • dan 4 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07752979

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

  • Kailera Clinical Site, San Antonio
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 85 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07793929

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  • UT Southwestern Med Center, Dallas
  • PlanIt Research, PLLC, Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • DM Clinical, Houston
  • DM Clinical, San Antonio
  • The Texas Liver Institute, San Antonio
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 8 hingga 18 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07253285

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Amarillo Medical Specialists, Amarillo
  • North Texas Endocrine Center, Dallas
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07720271

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

  • Endeavor Clinical Trials, San Antonio
Mengambil pesertaFasa 1
Umur 18 hingga 65 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07399678

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • Amarillo Med Spec LLP, Amarillo
  • Texas Diabetes & Endocrinology, Austin
  • Pinnacle Clinical Research, Brownsville
  • dan 7 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07668414

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • IMA Clinical Research Austin, Austin
  • Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville
  • Cedar Health Research - Texas Native Health, Dallas
  • dan 10 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  • PlanIt Research, LLC (Monitoring Room), Houston
  • PlanIt Research, LLC, Houston
  • VIP Trials, San Antonio
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07595549

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastroenterology Research of San Antonio, San Antonio
  • Southern Star Research Institute, San Antonio
  • Tyler Research Institute, Tyler
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Dell Children's Medical Center - PIN, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • McGovern Medical School, Houston
  • dan 4 lagi
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Gastroenterology Research of San Antonio, San Antonio
  • Southern Star Research Institute, San Antonio
  • Tyler Research Institute, Tyler
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • IMA Clinical Research Austin, Austin
  • Private Practice - Dr. Osvaldo A. Brusco, Corpus Christi
  • Velocity Clinical Research, Dallas, Dallas
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • UT Southwestern Medical Center, Dallas
  • Juno Research, Houston
  • Activian Clinical Research, Kingwood
  • dan 7 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, DeSoto
  • Research Site, El Paso
  • Research Site, Houston
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07784270

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • FutureSearch Trials of Neurology, Austin
  • Sleep Therapy Research Center, San Antonio
  • Consano Clinical Research, LLC, Shavano Park
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • PharmaTex Research, LLC, Amarillo
  • Austin Heart, Austin
  • Velocity Clinical Research - Austin, Austin
  • dan 22 lagi
Mengambil pesertaFasa 3
Umur 45 hingga 99 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • The University of Texas Health Science Center at Houston, Bellaire
  • Velocity Clinical Research, Dallas, Dallas
  • UT Southwestern Medical Center, Dallas
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • JCCT - Juno Bellaire Site, Bellaire
  • Epic Medical Research - DeSoto, DeSoto
  • Valley Institute of Research - Fort Worth, Fort Worth
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • IMA Clinical Research Austin, Austin
  • FutureSearch Trials of Dallas, Dallas
  • PlanIt Research, PLLC, Houston
  • dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07589608

Semaglutide for Post-Smoking Cessation Weight Management

  • The University of Texas at Austin, Austin
  • The University of Texas Health Science Center at Houston, Houston
Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
Umur 18 hingga 75 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06173778

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Austin
  • AURORA-1 Clinical Site, Brownsville
  • AURORA-1 Clinical Site, DeSoto
  • dan 8 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Austin
  • AURORA-2 Clinical Site, Brownsville
  • AURORA-2 Clinical Site, DeSoto
  • dan 10 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Headlands Research Brownsville, Brownsville
  • Velocity Clinical Research, Dallas
  • South Texas Research Institute - Edinburg, Edinburg
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Juno Research, Houston
  • Southern Endocrinology Associates, Mesquite
  • Texas Diabetes & Endocrinology, P.A., Round Rock
  • dan 2 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06897475

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Bellaire Clinical Research, LLC, Bellaire
  • South Texas Research Institute - Brownsville, Brownsville
  • South Texas Clinical Research, Corpus Christi
  • dan 8 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07351045

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

  • Epic Medical Research, DeSoto
  • Advanced Neurology Epilepsy and Sleep Center ANESC, El Paso
  • Biorhythms Center for Integrative Sleep Medicine, El Paso
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07571005

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Austin
  • ACCOMPLISH-2 Research Site, Farmers Branch
  • ACCOMPLISH-2 Research Site, Houston
  • dan 4 lagi
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
Umur 18 hingga 79 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  • Cedar Health Research, Dallas
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07770841

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

  • Epic Medical Research, DeSoto
  • Advanced Neurology Epilepsy and Sleep Center ANESC, El Paso
  • Biorhythms Center for Integrative Sleep Medicine, El Paso
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07571109

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • IMA Clinical Research Austin, Austin
  • Velocity Clinical Research, Dallas, Dallas
  • FutureSearch Trials of Dallas, Dallas
  • dan 3 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06143956

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • Mercy Family Clinic, Dallas
  • Velocity Clinical Research, Dallas, Dallas
  • Biopharma Informatic, LLC, Houston
  • dan 5 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07215559

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

  • ICON, San Antonio
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 55 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07767175

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  • Bellaire Dermatology Associates, Bellaire
  • Modern Research Associates, PLLC, Dallas
  • Center for Clinical Studies, Houston
  • dan 3 lagi
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06857942

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Amarillo
  • Kailera Clinical Site, Brownsville
  • Kailera Clinical Site, DeSoto
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Elligo Clinical Research Center, Austin
  • Johnson County Clinical Trials Juno Bellaire, Bellaire
  • Cedar Health Research, LLC, Dallas
  • dan 9 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Amarillo
  • Kailera Clinical Site, Bellaire
  • Kailera Clinical Site, DeSoto
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Elligo Clinical Research Center, Austin
  • Johnson County Clinical Trials Juno Bellaire, Bellaire
  • Osvaldo A Brusco MD PA, Corpus Christi
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07684144

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

  • ICON Early Phase Services, LLC, San Antonio
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 hingga 65 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07654972

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.